Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Treatment of malignant mesothelioma
Autore:
Jaklitsch, MT; Grondin, SC; Sugarbaker, DJ;
Indirizzi:
Brigham & Womens Hosp, Dept Surg, Div Thorac Surg, Boston, MA 02115 USA Brigham & Womens Hosp Boston MA USA 02115 orac Surg, Boston, MA 02115 USA Harvard Univ, Sch Med, Boston, MA 02115 USA Harvard Univ Boston MA USA 02115 vard Univ, Sch Med, Boston, MA 02115 USA Dana Farber Canc Inst, Boston, MA 02115 USA Dana Farber Canc Inst Boston MA USA 02115 Canc Inst, Boston, MA 02115 USA
Titolo Testata:
WORLD JOURNAL OF SURGERY
fascicolo: 2, volume: 25, anno: 2001,
pagine: 210 - 217
SICI:
0364-2313(200102)25:2<210:TOMM>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLEURAL MESOTHELIOMA; EXTRAPLEURAL PNEUMONECTOMY; MULTIMODALITY THERAPY; UNITED-STATES; CISPLATIN; CANCER; SIMIAN-VIRUS-40; DIFFUSE; MR; MANAGEMENT;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
60
Recensione:
Indirizzi per estratti:
Indirizzo: Jaklitsch, MT Brigham & Womens Hosp, Dept Surg, Div Thorac Surg, 75 Francis St, Boston, MA 02115 USA Brigham & Womens Hosp 75 Francis St Boston MA USA 02115 USA
Citazione:
M.T. Jaklitsch et al., "Treatment of malignant mesothelioma", WORLD J SUR, 25(2), 2001, pp. 210-217

Abstract

Malignant pleural mesothelioma (MPM) is a rare tumor that predominantly afflicts men over 50 years of age. Nearly 3000 MPMs are reported annually in the United States with the incidence expected to rise into the new millenium. Over the past 40 years, MPM has been unequivocally linked to asbestos exposure worldwide. Recently, however, a new theory on the carcinogenesis of this tumor has been proposed with the isolation of a simian virus (SV 40) like gene sequence in mesothelioma tumor cells. The clinical presentation ofMPM is variable, although most patients typically present with dyspnea, chest pain, or pleural effusion. Obtaining a diagnosis of MPM has been greatly assisted by video-assisted surgery and the use of immunohistochemistry and electron microscopic techniques, which help distinguish MPM from other tumor pathologies such as adenocarcinoma. Computed tomography and magnetic resonance imaging have been also useful for determining tumor burden and resectability. Traditionally, strategies for the treatment of MPM have includedsupportive care, surgery, radiotherapy, and chemotherapy. Survival with supportive care alone ranges between 4 and 12 months. Single-modality therapyusing traditional approaches (surgery, radiotherapy, chemotherapy) alone has failed to improve patient survival significantly. Recently, results using a multimodality approach have been favorable. In particular, cytoreductive surgery (pleuropneumonectomy) followed by sequential chemotherapy and radiotherapy have demonstrated improved survival, especially for patients,vithepithelial histology, negative resection margins, and no metastases to extrapleural lymph nodes. Innovative therapies such as the use of photodynamic, targeted cytokines and gene therapy are currently being investigated for management of MPM.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 18:49:23